Skip to main content
Premium Trial:

Request an Annual Quote

Lucigen Gets $226K SBIR Grant from NIH

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Wisconsin biotech firm Lucigen said on Monday it has received a $226,401 Small Business Innovation Research Phase I grant from the National Institutes of Health to develop genomic tools for use in discovering and characterizing new therapeutics from fungi.

Working with research partners from the University of Wisconsin, the company will identify compounds with potential antibiotic properties from the Aspergillus genus of fungi. The work will seek to discover biological compounds previously unknown to scientists and build a library of novel small molecules that will be studied for therapeutic applications, Lucigen said.

According to the firm, based in Middleton, Wis., the development of antibiotics has reached a level not seen since the 1940s as increasing numbers of bacteria become resistant to currently available drugs.

Lucigen develops products and technologies for gene cloning, genomics, and protein expression.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.